The product liability lawyers at Saiontz & Kirk, P.A. are now investigating potential claims for individuals who may be entitled to compensation through a Tylenol lawsuit as a result of liver failure or severe liver damage caused by side effects of acetaminophen. To review a potential claim for yourself, a… Read more.
Although Bayer AG agreed to stop marketing their heart surgery injection Trasylol in November 2007, they are now removing any remaining stock of the drug from the U.S. market following a study published in the New England Journal of Medicine. The Trasylol recall was issued after data from a Canadian… Read more.
Evidence continues to confirm that the heart surgery injection Trasylol greatly increases the risk of kidney complications and death. A Trasylol recall was issued last November following nearly two years of concerns about the drug’s link with reports of kidney damage and death. A recent report on CBS’s 60 Minutes… Read more.
According to a report which will be broadcast Sunday on CBS Television’s 60 Minutes, 22,000 deaths could have been prevented if Bayer and the FDA had issued a Trasylol recall earlier. Although a study was presented in January 2006 which demonstrated a link between Trasylol and serious side effects, the… Read more.
According to a recent report from the New York Post, at least 235 deaths could be blamed on Trasylol side effects. The heart surgery drug given to control bleeding has been linked to problems such as an increased risk of kidney damage, congestive heart failure, heart attacks and strokes. >>INFORMATION:… Read more.
The FDA announced today that they requested Bayer Pharmaceuticals halt further sales of Trasylol pending their review of data from a Canadian study which suggests that the heart surgery injection significantly increases the risk of death. The injection has been under scrutiny from regulators for nearly two years as a… Read more.
The FDA announced this week that they will take another look at the overall risks and benefits of Trasylol, a heart surgery injection used to control bleeding. Trasylol has been previously linked to an increased risk of serious and potentially fatal injuries, such as kidney failure, heart attacks and strokes. … Read more.
An FDA advisory panel met last week and found that a Trasylol recall is not warranted at this time, despite evidence that suggests the drug may increase the risk of kidney failure, heart failure, stroke and death. The recommendation was made after the panel of experts had an opportunity to… Read more.
According to FDA staff members, a heart bypass surgery injection known as Trasylol (aprotonin), appears to increase the risk of kidney failure, heart attacks, strokes and death. The statement was yesterday in advance of an advisory panel meeting scheduled to begin tomorrow. >>INFORMATION: Heart Bypass Surgery Injection Problems
The FDA will hold a second advisory panel meeting on September 12, 2007 to review the safety of Bayer AG’s heart surgery aprotonin injection, marketed as Trasylol. Following a prior meeting of experts in September 2006, regulators decided against a Trasylol recall and instead decided to require stronger warnings for… Read more.
